Benitec announced this week that it has received a Chinese patent covering the use of its expressed RNAi constructs against hepatitis C.

According to the company, the patent covers an expression cassette the encodes two of the RNAi molecules used in the HCV treatment under development by partner Tacere Therapeutics. Other sequences, including the third employed in Tacere's drug, will be the subject of separate patent applications, Benitec said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.